Immunome’s 2024 Financial Results and Pipeline Progress

Immunome, Inc. ( (IMNM) ) has released its Q4 earnings. Here is a breakdown of the information Immunome, Inc. presented to its investors.

Immunome, Inc. is a biotechnology company specializing in developing targeted cancer therapies, with a focus on first-in-class and best-in-class treatments. The company recently released its financial results for 2024, highlighting significant progress in its clinical pipeline and strategic initiatives. Key developments include the anticipated topline data for the Phase 3 RINGSIDE study of varegacestat in desmoid tumors expected in late 2025, the initiation of a Phase 1 trial for IM-1021, and the submission of an IND for IM-3050. Financially, Immunome reported a net loss of $293 million for 2024, with research and development expenses reaching $129.5 million. The company successfully raised $172.5 million in early 2025, extending its cash runway into 2027. Looking forward, Immunome aims to achieve several clinical milestones, supported by its robust financial position and ongoing development of its innovative oncology pipeline.